Search Results
Found 4 results
510(k) Data Aggregation
(160 days)
The Huntleigh Healthcare Ltd Sonicaid FM820 and FM830 Encore fetal monitors are indicated for use by trained healthcare professionals in non-invasive monitoring of physiological parameters in pregnant adult human females, and fetuses, during the intrapartum and antepartum periods of pregnancy. The devices are intended for use in clinical and hospital-type facilities. They are not intended for use in intensive care units, operating rooms or in transport monitoring applications.
Sonicaid FM820E is suitable for use when there is a need to monitor the following physiological parameters:
- . Single or twin fetal heart rates by means of ultrasound
- ◆ Fetal or maternal heart rate via ECG
- Uterine activity externally or internally sensed .
- . Fetal movement - maternally sensed.
Sonicaid FM830E is suitable for use when there is a need to monitor the following physiological parameters:
- . Single or twin fetal heart rates by means of ultrasound
- . Fetal or maternal heart rate via ECG
- Uterine activity externally or internally sensed .
- Fetal movement - maternally sensed.
- . Maternal heart rate and oxygen saturation via pulse oximetry
- . Maternal non-invasive blood pressure
The FM820E and FM830E are fetal/maternal monitors designed for use in clinical and hospital environments during the ante-partum and intra-partum phases of pregnancy.
Both units are designed for use at the bedside and the range includes a wall mounting bracket and a trolley for fixed or transportable use. The units may also be used free-standing on a work surface.
The FM820E and FM830E are powered from the local mains electrical supply.
The FM820E includes the following facilities:
- Monitoring of one or two fetal heart rates via two independent ultrasound transducers. .
- Monitoring of maternal uterine activity either via external (Toco) or internal (IUP) transducers. .
- Monitoring of maternal or fetal heart rate via ECG.
- . Capture of maternally sensed fetal movements via cabled switch.
- Display of vital signs parameters via colour LCD screen. .
- t Control interface via combination of dedicated and "soft" function buttons in conjunction with on-screen prompts.
- . Chart printout via inbuilt thermal printer.
- Connection to Central Monitoring System possible via RS232 or Ethernet. .
- Audio and visual alerts (user set limits).
The following facilities are provided on the FM830E model in addition to the above:
- . Monitoring of maternal oxygen saturation and heart rate via pulse oximetry sensor.
- Monitoring of maternal Non-Invasive Blood Pressure (NIBP) via inflatable cuff. .
The connections for the additional facilities are incorporated in a "side pod", which extends the area of the front panel. Field upgrade of the FM820E to FM830E specification is not allowed.
The provided text describes the Sonicaid FM800, a fetal/maternal monitor, and its comparison to predicate devices, but it does not include detailed acceptance criteria or a dedicated study definitively proving the device meets specific performance criteria in the format requested.
Instead, the document focuses on demonstrating substantial equivalence to existing legally marketed devices (Sonicaid FM830 (K002150) and RDT Limited Tempus IC™ Patient Monitor (K082718)) for FDA 510(k) premarket notification. This means the manufacturer is asserting their new device is as safe and effective as a device already on the market, rather than conducting a de novo study against pre-defined acceptance criteria for a novel device.
However, I can extract the relevant information and present what is available in a structured manner, highlighting the limitations.
Here's the breakdown of the information requested, based on the provided text:
Acceptance Criteria and Device Performance Study for Sonicaid FM800
Based on the provided FDA 510(k) summary for the Sonicaid FM800, the device aims to demonstrate substantial equivalence to predicate devices rather than meeting specific, explicitly stated acceptance criteria from a de novo study. Therefore, the "acceptance criteria" are implied by the performance of the predicate devices. The study conducted to support this is primarily comparative bench testing and reliance on OEM-provided clinical data.
1. A table of acceptance criteria and the reported device performance
Since specific, quantitative acceptance criteria are not explicitly defined in the document for general device performance (like sensitivity/specificity for a diagnostic device), I will use the comparison to the predicate device's characteristics and the documented performance improvements as a proxy.
Characteristic | Predicate Device (Sonicaid FM830 (K002150)) Performance | Submitted Device (Sonicaid FM830 Encore) Performance | Rationale/Implied "Acceptance" |
---|---|---|---|
Human Interface | Improved Presentation | ||
Display | Monochrome Electroluminescent 320x240 | Colour LCD 320x240 | Clearer user interface, reduced power consumption. |
Controls | Membrane type push buttons with dedicated and "soft" keys | Membrane type push buttons with dedicated and "soft" keys | Same, implying equivalence. |
Printer | 128mm Thick Film Thermal Array, 8 dots/mm | 128mm Thick Film Thermal Array, 8 dots/mm | Same, implying equivalence. |
Connectors | (Varied connector types) | (Updated connector types) | Modernized, improved patient isolation (plastic vs metal for MSpO2). |
Power Requirements | Auto-switches 100-120 & 200-240Vac; 100VA max. | 90-240Vac; 100VA max. | Increased supply flexibility, same consumption. Implies improved adaptability. |
Ultrasound | Improved Signal Processing & Reduced Acoustic Output | ||
Transducers - Physical | 74x27mm (Dia x Height); 7-element piezo | 79x27mm (Dia x Height); 8-element piezo | Similar, implies functional equivalence. |
Transducers - Frequency | 1.5MHz (US1) and 2MHz (US2) | 1MHz (both channels) | Improved pickup & discrimination with new software. |
Measured Acoustic Output (Ispta) (FDA Track 1) | 1.5MHz: 11mW cm-2; 2.0MHz: 7.3mW cm-2 | 2.1mW cm-2 | Superior signal processing enabled reduction in acoustic power output (a safety improvement). |
Audio Feedback | Analogue | Digital | Improved artefact rejection, better audibility at 1MHz. |
Tocograph | Improved Patient Comfort & Maintenance | ||
Transducers - Physical | Floating piston type with adhesive membrane. | New moulding, similar to u/s with overmoulded elastomer faceplate. | Lower maintenance, improved patient comfort, easier to clean, reduced infection risk. |
MECG/FECG | Performance Improvement under Sub-optimal Conditions | ||
Signal Processing | Analogue/digital. | Analogue/digital (enhanced) | Performance improvement under sub-optimal conditions. |
NIBP | Suntech Alta OEM Technology | Suntech Advantage OEM Technology | Superseded, implying updated and equivalent/improved performance. |
MSPO2 | BCI (Smiths Medical) WW3711 "B2" OEM Technology | BCI (Smiths Medical) WW3711 "B2" OEM Technology | Same OEM module, ensuring equivalent performance. |
Software | Not implemented (CTG Trace) | Trace data stored in memory for review on screen - up to 72 hours. | Product improvement (enhanced functionality). |
2. Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective)
- Test Set Sample Size:
- For non-clinical bench testing: The document does not specify a "sample size" in terms of number of cases or patients for the comparative bench testing (document 7515101 - FM800E Comparative Bench Test Summary) or the MsP02 verification protocol (document 7514502), although these would involve laboratory tests on the device itself.
- For clinical tests: "No specific clinical tests were carried out to determine substantial equivalence." The submission references clinical trials carried out by the OEM providers of the SpO2 technology, but the sample size for these external OEM trials is not provided within this document. User evaluation trials are proposed but not yet completed at the time of submission.
- Data Provenance:
- Bench Testing: Conducted internally by Huntleigh Healthcare Ltd. (United Kingdom). This would be prospective for the submitted device, comparing it against the predicate.
- OEM SpO2 Clinical Trials: Conducted by BCI (Smiths Medical). The country of origin and whether these were retrospective or prospective are not specified in this document.
3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience)
- The document does not mention using experts to establish ground truth for the test set as part of its own substantial equivalence testing. The primary test method was comparative bench testing against a predicate device.
- For the OEM SpO2 clinical trials, details about expert involvement for ground truth are not provided in this submission.
4. Adjudication method (e.g. 2+1, 3+1, none) for the test set
- No adjudication method is mentioned for any test set within this submission. The tests performed are primarily engineering bench tests or rely on external OEM clinical data.
5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance
- No MRMC study was done. This device is a medical monitor, not an AI-powered diagnostic imaging tool that would typically involve human readers. The document states that user evaluation trials are proposed to verify effectiveness in clinical situations, but these are not described as MRMC studies and were not completed at the time of submission.
6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done
- The device is a monitor that provides physiological parameters. Its performance is inherent in its measurement accuracy and display, which can be evaluated in a standalone manner (e.g., how accurately it measures heart rate or blood pressure compared to a reference). The "Comparative bench tests" confirm this standalone performance. No specific standalone performance metrics (e.g., algorithm only) as might be seen in an AI context are provided, but the device itself has standalone performance.
7. The type of ground truth used (expert consensus, pathology, outcomes data, etc)
- For the bench tests, the "ground truth" is typically established by using calibrated reference equipment or standards to ensure the new device's readings are accurate and comparable to the predicate device.
- For the OEM SpO2 clinical trials, the type of ground truth for oxygen saturation would likely involve co-oximetry, the gold standard for blood oxygen measurement. However, this is not detailed in the provided text.
8. The sample size for the training set
- The device is a traditional medical monitor; it is not described as utilizing machine learning or artificial intelligence that would require a "training set" in the computational sense. The "improved signal processing" or "enhanced" algorithms refer to conventional digital signal processing, not AI model training. Therefore, this question is not applicable.
9. How the ground truth for the training set was established
- This question is not applicable as there is no "training set" for an AI model mentioned for this device.
Ask a specific question about this device
(54 days)
The Dolphin 2000 Oximetry Sensors are indicated for use in continuous monitoring of arterial oxygen saturation and pulse rate.
The Dolphin 2000 Oximetry Sensors are fully compatible disposable and re-usable replacement sensors for use with Nellcor pulse oximeter monitors. They represent a design change to the Dolphin 2000 BCI Compatible Sensors.
The disposable Dolphin 2000 Oximetry Sensors are constructed in a similar manner to predicate devices. The emitter and detector diodes are embedded in a laminate of tapes that is connected to the cable assembly. The sensors have an adhesive bandage backing that allows the sensor to be applied to the patient by wrapping it around a finger or toe (measurement site). Four sizes of disposable Dolphin 2000 Oximetry Sensors are available, which are indicated for use for adult, pediatric, infant and neonatal application sites. The Dolphin 2000 disposable sensors are provided non-sterile for single patient use.
The re-usable Dolphin 2000 Finger Clip Oximetry Sensor is an adult-sized clothespinstyle clip that is placed on the end of a finger. The finger clip sensor consists of the emitter and detector components mounted in opposing clip halves, maintained in mild compression by a spring hinge. The molded outer components house the optoelectric components within contoured pads that maintain contact with the patient's finger. Clear windows within these pads permit the optical energy to pass through the finger for the measurements. The Dolphin 2000 re-usable sensors are provided non-sterile.
The Dolphin 2000 Oximetry Sensors were validated in clinical testing to demonstrate their accuracy in measuring arterial oxygen saturation (SpO2).
1. Table of Acceptance Criteria and Reported Device Performance:
Parameter | Acceptance Criteria (Clinical Validation) | Reported Device Performance (Clinical Validation) |
---|---|---|
ARMS for Reusable, Adult Disposable, and Pediatric/Infant Disposable probes |
Ask a specific question about this device
(64 days)
Replacement battery for Nellcor, Inc. 0810-0103 N-200 Pulse Oximeter with Factory Replacement Block, 510(k) Number K863784.
This battery is shipped only to customers who request a replacement battery for a particular device or to replace a competitor's replacement battery. The biomedical equipment technician therefore knows the intended use is as a replacement battery.
Replacement battery for Nellcor, Inc. 0810-0103 N-200 Pulse Oximeter with Factory Replacement Block, 510(k) Number K863784.
I am sorry, but the provided text does not contain the information requested in your prompt. The document is a 510(k) clearance letter from the FDA for a replacement battery, and it primarily focuses on the regulatory approval and substantial equivalence determination for this specific device. It does not include any details about acceptance criteria, performance studies, sample sizes, expert qualifications, or ground truth establishment relevant to an AI/ML device.
Ask a specific question about this device
(567 days)
Sathlaster is intended for use an adjunct to traditional Pulse Oximetry, in which the caregiver observes instantaneous Pulse Oximetry values as displayed on a Pulse Oximeter's face. SatMaster produces graphs and statistics describing a patient's Pulse Oximerry data trends over relatively long periods of time, including those times when the caregiver is not directly observing the Pulse Oximeter's display.
SatMaster is the name of EMG Scientific's Computerized Pulse Oximetry Software product. This product consists of a Program Diskette, a Software License, a User Manual, and a Test Cable. Thus, SatMaster is a software-only "device," intended for use with an MS-DOS, PC-type computer provided by the end-user. Briefly, the SatMaster software provides a PC computer user the capability of transferring Pulse Oximetry data from a Pulse Oximeter, storing the data on the computer, displaying the data in various forms, annotating the data, calculating statistics, and printing the results.
The provided document is a 510(k) Summary for a software device called "SatMaster," a Computerized Pulse Oximetry Software. This type of document is submitted to the FDA to demonstrate substantial equivalence to a legally marketed predicate device, rather than to establish new safety and effectiveness through a clinical study with acceptance criteria.
Therefore, the document does NOT contain the following information:
- A table of acceptance criteria and reported device performance.
- Sample sizes used for a test set or data provenance for such a test set.
- Number of experts or their qualifications for establishing ground truth for a test set.
- Adjudication method for a test set.
- Results of a multi-reader multi-case (MRMC) comparative effectiveness study, or any effect size related to AI improvement.
- Details of a standalone (algorithm only) performance study.
- Type of ground truth used (e.g., pathology, outcomes data) for a test set.
- Sample size for a training set.
- How ground truth for a training set was established.
Analysis of the Provided Information:
The document focuses on demonstrating that SatMaster is substantially equivalent to a predicate device (Nellcor N-250 Pulse Oximeter, which is a combination of Nellcor N-200 Pulse Oximeter and Nellcor N-50 Powerbase).
Instead of clinical studies with acceptance criteria, the document provides:
- Device Description and Intended Use: SatMaster is a software-only device that transfers, stores, displays, annotates, calculates statistics, and prints pulse oximetry data from approved pulse oximeters. It is intended as an accessory to enhance a caregiver's use of Pulse Oximeters, providing trends over long periods.
- Comparison to Predicate Device:
- Equivalence: SatMaster performs similar functions to the Nellcor N-50 Powerbase portion of the N-250, such as extracting data, displaying trend information, producing tabular lists, and generating histograms of SaO2 levels.
- Differences: SatMaster is not a patient monitor, does not provide alarms or ECG/Pleth waveform output, does not power the oximeter, and provides additional reports and data-management functions not present in the predicate device.
- Safety and Effectiveness Argument:
- The document argues that SatMaster's use should have no impact on the safety of the Pulse Oximetry monitoring process because the Pulse Oximeter itself (an approved device) performs the primary monitoring, and SatMaster only processes the data after collection.
- It states that SatMaster software has been "designed and extensively tested to insure the correctness and accuracy of SatMaster's data retrieval, data management, data storage, statistical calculations, and reports." However, no details about these tests (e.g., methodology, sample sizes, specific metrics, or acceptance criteria) are provided.
- It claims enhancements in safety and effectiveness compared to the predicate device, such as requiring patient ID entry (reducing mix-up risk) and generating more extensive reports.
- It cites published articles describing research performed using SatMaster by various researchers, implying its clinical value. This is anecdotal evidence of device utility rather than a formal study proving specific performance metrics against defined acceptance criteria.
In summary, to directly answer the request, the provided 510(k) summary does not contain the information typically found in a study demonstrating a device meets acceptance criteria. It relies on a demonstration of substantial equivalence to an existing device and general statements about testing and clinical utility, rather than specific performance metrics against established thresholds.
Ask a specific question about this device
Page 1 of 1